Energy 90.5 Top Music Radio
Amylyx Pharmaceuticals announced Friday that its drug for amyotrophic lateral sclerosis, or ALS, called Relyvrio, did not show significant benefit in a large clinical trial and may be withdrawn from the market. Read More Breaking News, Latest News and Videos | CNN
Copyright © 2025. All Rights Reserved.Chole Broadcasting